Meet IAG’s Bio-Partnering Team at H.C. Wainwright Global Life Sciences Conference 2021
IAG’s team will be attending H.C. Wainwright Global Life Sciences Conference, 9-10 March 2021 to meet meet clinical stage biotech companies developing novel treatments to address unmet patients’ needs.
IAG’s Bio-Partnering team is focused on building a diversified portfolio of innovative life science companies at various stages of clinical development.
‘At IAG, by bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry’, said David Chia, IAG’s Head of Bio-Partnering.
Collaboratively, with the best academics of our time we are building mechanisms for early visibility of study performance through our DYNAMIKA platform. When needed and at the right time, our venture partners and analysts support development of the tailored strategies for potential M&As.
‘Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models’, added Dr. Olga Kubassova, CEO of IAG.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: http://www.ia-grp.com/trial-solutions/bio-partnering/
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. www.ia-grp.com
Engage with our team
Dr. Olga Kubassova, CEO: https://www.linkedin.com/in/olgakubassova/
David Chia, CCO: https://www.linkedin.com/in/jahyungdavidchia/
Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer: https://www.linkedin.com/in/dianaroettger/